Current status of renin-aldosterone angiotensin system-targeting anti-hypertensive drugs as therapeutic options for Alzheimer's disease

Expert Opinion on Investigational Drugs

Volumn 22, Issue 10, 2013, Pages 1229-1242

  Ashby, Emma Louise ^a   Kehoe, Patrick G ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Alzheimer's disease; Angiotensin; Angiotensin II; Angiotensin converting enzyme; Angiotensin converting enzyme inhibitor; Angiotensin receptor blocker; Anti hypertensives; Hypertension; Renin; Renin inhibitor

Indexed keywords

3 PHENYLSULFONYL 8 (1 PIPERAZINYL)QUINOLINE; ALISKIREN; ALPHA TOCOPHEROL; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; AVAGACESTAT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIRECT RENIN INHIBITOR; DIURETIC AGENT; DONEPEZIL; ENALAPRIL; FOSINOPRIL; GALANTAMINE; IMMUNOGLOBULIN; LISINOPRIL; LUAE 58054; MEMANTINE; PERINDOPRIL; POTASSIUM SPARING DIURETIC AGENT; RAMIPRIL; RENIN INHIBITOR; RIVASTIGMINE; SOLANEZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSARTAN; VANUTIDE CRIDIFICAR;

ALZHEIMER DISEASE; CARDIOVASCULAR RISK; CENTRAL NERVOUS SYSTEM; CEREBROVASCULAR ACCIDENT; COGNITION; DEMENTIA; DISEASE ASSOCIATION; HUMAN; HYPERTENSION; MILD COGNITIVE IMPAIRMENT; NEUROPATHOLOGY; NONHUMAN; PATHOGENESIS; PERIPHERAL HYPERTENSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

ALZHEIMER DISEASE; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CEREBROVASCULAR CIRCULATION; CLINICAL TRIALS AS TOPIC; COGNITION; HUMANS; HYPERTENSION; RENIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 84884271395     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2013.812631     Document Type: Review

References (100)

1. Karantzoulis S, Galvin JE. Distinguishing Alzheimer's disease from other major forms of dementia. Expert Rev Neurother 2011;11(11):1579-91
2. Hebert LE, Weuve J, Scherr PA, et al. Alzheimer disease in the United States (2010-2050) estimated using the 2010 census. Neurology 2013;80(19):1778-83
3. Grinberg LT, Heinsen H. Toward a pathological definition of vascular dementia. J Neurol Sci 2010;299(1-2):136-8
4. Jellinger KA. Pathology and pathogenesis of vascular cognitive impairment-a critical update. Front Aging Neurosci 2013;5:17
5. Neef D, Walling AD. Dementia with Lewy bodies: an emerging disease. Am Fam Physician 2006;73(7):1223-9
6. Kehoe PGW, Gordon K. The renin angiotensin system in Alzheimer's disease -do updates highlight a clinical and biological dichotomy?Curr Alzheimer Res 2006;3(2):171
7. Kehoe PG, Passmore PA. The renin-angiotensin system and antihypertensive drugs in Alzheimer's disease: current standing of the angiotensin hypothesis?J Alzheimers Dis 2012;30(Suppl 2):S251-68
8. Goodison WV, Frisardi V, Kehoe PG. Calcium channel blockers and Alzheimer's disease: potential relevance in treatment strategies of metabolic syndrome. J Alzheimers Dis 2012;30(0):S269-82
9. Callaway E. Alzheimer's drugs take a new tack. Nature 2012;489(7414):13-14
10. Aisen PS, Vellas B, Hampel H. Moving towards early clinical trials for amyloid-targeted therapy in Alzheimer's disease. Nat Rev Drug Discov 2013;12(4):324
11. ClinicalTrials.gov. Available from: wwwclinicaltrialsgov [Last accessed 16 May 2013]
12. Power MC, Weuve J, Gagne JJ, et al. The association between blood pressure and incident Alzheimer disease: a systematic review and meta-analysis. Epidemiology 2011;22(5):646-59
13. Rodrigue KM, Rieck JR, Kennedy KM, et al. Risk factors for beta-amyloid deposition in healthy aging. JAMA Neurol 2013;70(5):600-6
14. Mangialasche F, Solomon A, Winblad B, et al. Alzheimer's disease: clinical trials and drug development. Lancet Neurol 2010;9(7):702-16
15. Fyhrquist F, Saijonmaa O. Renin-angiotensin system revisited. J Intern Med 2008;264(3):224-36
16. Kanaide H, Ichiki T, Nishimura J, et al. Cellular mechanism of vasoconstriction induced by angiotensin II: it remains to be determined. Circ Res 2003;93(11):1015-17
17. Mogi M, Iwanami J, Horiuchi M. Roles of brain angiotensin II in cognitive function and dementia. Int J Hypertens 2012;2012:169649
18. Bodineau L, Frugiere A, Marc Y, et al. Orally active aminopeptidase A inhibitors reduce blood pressure: a new strategy for treating hypertension. Hypertension 2008;51(5):1318-25
19. Yagil Y, Yagil C. Hypothesis: ACE2 modulates blood pressure in the mammalian organism. Hypertension 2003;41(4):871-3
20. Atlas SA. The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition. J Manag Care Pharm 2007;13(8 Suppl B):9-20
21. UK National Statistics. Available from: wwwstatisticsgovuk/hub/indexhtml [Last accessed 18 March 2013]
22. Sink KM, Leng X, Williamson J, et al. Angiotensin-converting enzyme inhibitors and cognitive decline in older adults with hypertension: results from theCardiovascular Health Study. Arch Intern Med 2009;169(13):1195-202
23. Michel MC, Foster C, Brunner HR, et al. A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists. Pharmacol Rev 2013;65(2):809-48
24. Tzourio C, Anderson C, Chapman N, et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med 2003;163(9):1069-75
25. Angeli F, Reboldi G, Mazzotta G, et al. Safety and efficacy of aliskiren in the treatment of hypertension and associated clinical conditions. Curr Drug Saf 2012;7(1):76-85
26. Zhu D, Shi J, Zhang Y, et al. Central angiotensin II stimulation promotes beta amyloid production in Sprague Dawley rats. PLoS One 2011;6(1):e16037
27. Diaz-Ruiz C, Wang J, Ksiezak-Reding H, et al. Role of hypertension in aggravating abeta neuropathology of AD type and tau-mediated motor impairment. Cardiovasc Psychiatry Neurol 2009;2009:107286
28. Joas E, Backman K, Gustafson D, et al. Blood pressure trajectories from midlife to late life in relation to dementia in women followed for 37 years. Hypertension 2012;59(4):796-801
29. Launer LJ, Ross GW, Petrovitch H, et al. Midlife blood pressure and dementia: the Honolulu-Asia aging study. Neurobiol Aging 2000;21(1):49-55
30. Schneider P, Buerger K, Teipel S, et al. Antihypertensive therapy is associated with reduced rate of conversion to Alzheimer's disease in midregional proatrial natriuretic peptide stratified subjects with mild cognitive impairment. Biol Psychiatry 2011;70(2):145-51
31. Diaz-Ruiz C, Wang J, Ksiezak-Reding H, et al. Role of hypertension in aggravating Ab neuropathology of AD type and tau-mediated motor impairment. Cardiovasc Psychiatry Neurol 2009;2009(9; Article ID 107286
32. Hoffman LB, Schmeidler J, Lesser GT, et al. Less Alzheimer disease neuropathology in medicated hypertensive than nonhypertensive persons. Neurology 2009;72(20):1720-6
33. Petrovitch H, White LR, Izmirilian G, et al. Midlife blood pressure and neuritic plaques, neurofibrillary tangles, and brain weight at death: the HAAS. Honolulu-Asia aging Study. Neurobiol Aging 2000;21(1):57-62
34. Austin BP, Nair VA, Meier TB, et al. Effects of hypoperfusion in Alzheimer's disease. J Alzheimers Dis 2011;26(Suppl 3):123-33
35. Wang J, Ho L, Chen L, et al. Valsartan lowers brain beta-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease. J Clin Invest 2007;117(11):3393-402
36. Danielyan L, Klein R, Hanson LR, et al. Protective effects of intranasal losartan in the APP/PS1 transgenic mouse model of Alzheimer disease. Rejuvenation Res 2010;13(2-3):195-201
37. Davies NM Kehoe PG, et al. Associations of anti-hypertensive treatments with Alzheimer's disease, vascular dementia, and other dementias. J Alzheimers Dis 2011;26(4):699-708
38. Li NC, Lee A, Whitmer RA, et al. Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ 2010;340:b5465
39. Forette F, Seux ML, Staessen JA, et al. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med 2002;162(18):2046-52
40. Khachaturian AS, Zandi PP, Lyketsos CG, et al. Antihypertensive medication use and incident Alzheimer disease: the Cache County Study. Arch Neurol 2006;63(5):686-92
41. Ohrui T, Tomita N, Sato-Nakagawa T, et al. Effects of brain-penetrating ACE inhibitors on Alzheimer disease progression. Neurology 2004;63(7):1324-5
42. Hebert PL, McBean AM, O'Connor H, et al. Time until incident dementia among Medicare beneficiaries using centrally acting or non-centrally acting ACE inhibitors. Pharmacoepidemiol Drug Saf 2013; Epub ahead of print
43. Solfrizzi V, Scafato E, Frisardi V, et al. Angiotensin-converting enzyme inhibitors and incidence of mild cognitive impairment. The Italian Longitudinal Study on Aging. Age (Dordr) 2011;35(2):441-53
44. Kehoe PG Davies NM, et al. Associations of angiotensin targeting antihypertensive drugs with mortality and hospitalization in primary care patients with dementia. J Alzheimers Dis 2013;33(4):999-1008
45. Kehoe PG, Davies NM, Martin RM, et al. Associations of angiotensin targeting antihypertensive drugs with mortality and hospitalization in primary care patients with dementia. J Alzheimers Dis 2013;33(4):999-1008
46. Khachaturian AS, Zandi PP, Lyketsos CG, et al. Antihypertensive medication use and incident Alzheimer disease: the cache county study. Neuropsychopharmacology 2006;31:S39-S
47. Fournier A, Oprisiu-Fournier R, Serot JM, et al. Prevention of dementia by antihypertensive drugs: how AT1-receptor-blockers and dihydropyridines better prevent dementia in hypertensive patients than thiazides and ACE-inhibitors. Expert Rev Neurother 2009;9(9):1413-31
48. Staessen JA, Thijs L, Richart T, et al. Placebo-controlled trials of blood pressure-lowering therapies for primary prevention of dementia. Hypertension 2011;57(2):e6-7
49. Wharton W, Stein JH, Korcarz C, et al. The effects of ramipril in individuals at risk for Alzheimer's disease: results of a pilot clinical trial. J Alzheimers Dis 2012;32(1):147-56
50. Lithell H, Hansson L, Skoog I, et al. The Study on COgnition and Prognosis in the Elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomization. J Hypertens 2004;22(8):1605-12
51. Anderson C, Teo K, Gao P, et al. Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies. Lancet Neurol 2011;10(1):43-53
52. Hajjar I, Hart M, Chen Y-L, et al. Effect of antihypertensive therapy on cognitive function in early executive cognitive impairment: a double-blind randomized clinical trial. Arch Intern Med 2012;172(5):442-4
53. Hajjar I, Hart M, Chen YL, et al. Antihypertensive therapy and cerebral hemodynamics in executive mild cognitive impairment: results of a pilot randomized clinical trial. J Am Geriatr Soc 2013;61(2):194-201
54. Hajjar I, Brown L, Mack WJ, Chui H. Impact of angiotensin receptor blockers on alzheimer disease neuropathology in a large brain autopsy series. Arch Neurol 2012;69(12):1632-8
55. Fogari R, Mugellini A, Zoppi A, et al. Influence of losartan and atenolol on memory function in very elderly hypertensive patients. J Hum Hypertens 2003;17(11):781-5
56. Fogari R, Mugellini A, Zoppi A, et al. Effect of telmisartan/ hydrochlorothiazide vs lisinopril/hydrochlorothiazide combination on ambulatory blood pressure and cognitive function in elderly hypertensive patients. J Hum Hypertens 2006;20(3):177-85
57. Peters R, Beckett N, Forette F, et al. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurol 2008;7(8):683-9
58. Dong YF, Kataoka K, Toyama K, et al. Attenuation of brain damage and cognitive impairment by direct renin inhibition in mice with chronic cerebral hypoperfusion. Hypertension 2011;58(4):635-42
59. Chen SD, Wu CL, Lin TK, et al. Renin inhibitor aliskiren exerts neuroprotection against amyloid beta-peptide toxicity in rat cortical neurons. Neurochem Int 2012;61(3):369-77
60. Miners JS, Barua N, Kehoe PG, et al. Abeta-degrading enzymes: potential for treatment of Alzheimer disease. J Neuropathol Exp Neurol 2011;70(11):944-59
61. Hu J, Igarashi A, Kamata M, et al. Angiotensin-converting enzyme degrades Alzheimer amyloid beta-peptide (A beta); retards A beta aggregation, deposition, fibril formation; and inhibits cytotoxicity. J Biol Chem 2001;276(51):47863-8
62. Oba R, Igarashi A, Kamata M, et al. The N-terminal active centre of human angiotensin-converting enzyme degrades Alzheimer amyloid beta-peptide. Eur J Neurosci 2005;21(3):733-40
63. Hemming ML, Selkoe DJ. Amyloid beta-protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor. J Biol Chem 2005;280(45):37644-50
64. Zou K, Yamaguchi H, Akatsu H, et al. Angiotensin-converting enzyme converts amyloid beta-protein 1-42 (Abeta(1-42)) to Abeta(1-40), and its inhibition enhances brain Abeta deposition. J Neurosci 2007;27(32):8628-35
65. Miners JS, Ashby E, Van Helmond Z, et al. Angiotensin-converting enzyme (ACE) levels and activity in Alzheimer's disease, and relationship of perivascular ACE-1 to cerebral amyloid angiopathy. Neuropathol Appl Neurobiol 2008;34(2):181-93
66. Kehoe PG, Passmore PA. The renin-angiotensin system and antihypertensive drugs in Alzheimer's disease: current standing of the angiotensin hypothesis?J Alzheimers Dis 2012;30(Suppl 2):S251-68
67. Miners JS, Baig S, Palmer J, et al. Abeta-degrading enzymes in Alzheimer's disease. Brain Pathol 2008;18(2):240-52
68. Miners JS, Raiker M, Love S, et al. ACE variants and association with brain Ab levels in Alzheimer's disease. Am J Transl Res 2010;3(1):8
69. Alzheimer Research Forum alzgene. Available from: http://wwwalzgeneorg/ geneoverviewasp?geneid=125 [Last accessed 18 March 2013]
70. Belbin O, Brown K, Shi H, et al. A multi-center study of ACE and the risk of late-onset Alzheimer's disease. J Alzheimers Dis 2011;24(3):587-97
71. Feulner TM, Laws SM, Friedrich P, et al. Examination of the current top candidate genes for AD in a genome-wide association study. Mol Psychiatry 2010;15(7):756-66
72. Miners S, Ashby E, Baig S, et al. Angiotensin-converting enzyme levels and activity in Alzheimer's disease: differences in brain and CSF ACE and association with ACE1 genotypes. Am J Transl Res 2009;1(2):163-77
73. Gebke E, Muller AR, Jurzak M, et al. Angiotensin II-induced calcium signalling in neurons and astrocytes of rat circumventricular organs. Neuroscience 1998;85(2):509-20
74. Guimaraes PB, Alvarenga EC, Siqueira PD, et al. Angiotensin II binding to angiotensin I-converting enzyme triggers calcium signaling. Hypertension 2011;57(5):965-72
75. Mogi M, Tsukuda K, Li JM, et al. Inhibition of cognitive decline in mice fed a high-salt and cholesterol diet by the angiotensin receptor blocker, olmesartan. Neuropharmacology 2007;53(8):899-905
76. Takeda S, Sato N, Takeuchi D, et al. Angiotensin receptor blocker prevented beta-amyloid-induced cognitive impairment associated with recovery of neurovascular coupling. Hypertension 2009;54(6):1345-52
77. Mogi M, Li JM, Tsukuda K, et al. Telmisartan prevented cognitive decline partly due to PPAR-gamma activation. Biochem Biophys Res Commun 2008;375(3):446-9
78. Tsukuda K, Mogi M, Iwanami J, et al. Cognitive deficit in amyloid-beta-injected mice was improved by pretreatment with a low dose of telmisartan partly because of peroxisome proliferator-activated receptor-gamma activation. Hypertension 2009;54(4):782-7
79. Tota S, Kamat PK, Awasthi H, et al. Candesartan improves memory decline in mice: involvement of AT1 receptors in memory deficit induced by intracerebral streptozotocin. Behav Brain Res 2009;199(2):235-40
80. Hua F, Zhou J, Liu J, et al. Glycogen synthase kinase-3beta negatively regulates TGF-beta1 and Angiotensin II-mediated cellular activity through interaction with Smad3. Eur J Pharmacol 2010;644(1-3):17-23
81. Pohanka M. Acetylcholinesterase inhibitors: a patent review (2008 -present). Expert Opin Ther Patents 2012;22(8):871-86
82. Doughan AK, Harrison DG, Dikalov SI. Molecular mechanisms of angiotensin II-mediated mitochondrial dysfunction: linking mitochondrial oxidative damage and vascular endothelial dysfunction. Circ Res 2008;102(4):488-96
83. de Cavanagh EM, Ferder M, Inserra F, et al. Angiotensin II, mitochondria, cytoskeletal, and extracellular matrix connections: an integrating viewpoint. Am J Physiol Heart Circ Physiol 2009;296(3):H550-8
84. Abadir PM, Foster DB, Crow M, et al. Identification and characterization of a functional mitochondrial angiotensin system. Proc Natl Acad Sci USA 2011;108(36):14849-54
85. Wosik K, Cayrol R, Dodelet-Devillers A, et al. Angiotensin II controls occludin function and is required for blood brain barrier maintenance: relevance to multiple sclerosis. J Neurosci 2007;27(34):9032-42
86. Zhang M, Mao Y, Ramirez SH, et al Angiotensin II induced cerebral microvascular inflammation and increased blood-brain barrier permeability via oxidative stress. Neuroscience 2010;171(3):852-8
87. Fleegal-DeMotta MA, Doghu S, Banks WA. Angiotensin II modulates BBB permeability via activation of the AT(1) receptor in brain endothelial cells. J Cereb Blood Flow Metab 2009;29(3):640-7
88. Frolkis I, Gurevitch J, Yuhas Y, et al. Interaction between paracrine tumor necrosis factor-alpha and paracrine angiotensin II during myocardial ischemia. J Am Coll Cardiol 2001;37(1):316-22
89. Del Prete D, Gambaro G, Lupo A, et al. Precocious activation of genes of the renin-angiotensin system and the fibrogenic cascade in IgA glomerulonephritis. Kidney Int 2003;64(1):149-59
90. Lanz TV, Ding Z, Ho PP, et al. Angiotensin II sustains brain inflammation in mice via TGF-beta. J Clin Invest 2010;120(8):2782-94
91. Sengul G, Coskun S, Cakir M, et al. Neuroprotective effect of ACE inhibitors in glutamate -induced neurotoxicity: rat neuron culture study. Turk Neurosurg 2011;21(3):367-71
92. Mogi M, Li JM, Iwanami J, et al. Angiotensin II type-2 receptor stimulation prevents neural damage by transcriptional activation of methyl methanesulfonate sensitive 2. Hypertension 2006;48(1):141-8
93. Li J, Culman J, Hortnagl H, et al. Angiotensin AT2 receptor protects against cerebral ischemia-induced neuronal injury. FASEB J 2005;19(6):617-19
94. Jing F, Mogi M, Sakata A, et al. Direct stimulation of angiotensin II type 2 receptor enhances spatial memory. J Cereb Blood Flow Metab 2012;32(2):248-55
95. Corbett A, Pickett J, Burns A, et al. Drug repositioning for Alzheimer's disease. Nat Rev Drug Discov 2012;11(11):833-46
96. Kehoe PG, Miners S, Love S. Angiotensins in Alzheimer's disease -friend or foe?Trends Neurosci 2009;32(12):619-28
97. Carson JA, Turner AJ. Beta-amyloid catabolism: roles for neprilysin (NEP) and other metallopeptidases?J Neurochem 2002;81(1):1-8
98. Golding BJ, Overall AD, Brown G, et al. Strain differences in the effects of angiotensin IV on mouse cognition. Eur J Pharmacol 2010;641(2-3):154-9
99. Wright JW, Harding JW. Brain renin-angiotensin-a new look at an old system. Prog Neurobiol 2011;95(1):49-67
100. Tian M, Zhu D, Xie W, et al. Central angiotensin II-induced Alzheimer-like tau phosphorylation in normal rat brains. FEBS Lett 2012;586(20):3737-45